N-Acetylcysteine Use in Pregnancy
N-acetylcysteine (NAC) is safe to use during pregnancy based on animal studies showing no teratogenic effects and emerging clinical evidence demonstrating safety and potential benefits in specific pregnancy complications. 1
Safety Profile
The FDA drug label explicitly states that animal reproduction studies in rats and rabbits at doses up to 2.6 times the human mucolytic dose revealed no evidence of impaired fertility or harm to the fetus due to acetylcysteine 1. Specifically:
- Teratology studies in rabbits showed NAC was nonteratogenic at oral doses of 500 mg/kg/day (2.6 times human dose) administered during organogenesis
- Rat studies with aerosol exposure throughout gestation and postpartum showed no adverse effects on dams or newborns
- No teratogenic effects were observed in multiple animal models
However, the label includes the standard caveat that "there are no adequate and well-controlled studies in pregnant women" and recommends use "only if clearly needed" 1.
Clinical Indications in Pregnancy
Acute Fatty Liver of Pregnancy (AFLP)
NAC can be considered in women with AFLP requiring intensive care admission, though evidence is limited. The 2023 EASL guidelines note that while there are no existing data to definitively support or refute NAC benefit in AFLP, benefits have been demonstrated in other causes of non-acetaminophen-induced liver failure 2. This represents a weak recommendation based on extrapolation from other liver failure contexts.
Acetaminophen Toxicity
NAC is the established treatment for acetaminophen overdose in pregnancy. A case report demonstrates successful use of the standard 20-hour intravenous NAC protocol in a pregnant woman at 32 weeks gestation, resulting in full-term delivery without sequelae 3.
Emerging Indications with Promising Evidence
Intrauterine infection/inflammation (Triple I): A 2021 randomized trial showed that intrapartum intravenous NAC in women with confirmed Triple I resulted in:
- Significantly improved newborn status at birth
- Reduced composite neonatal morbidity (21% vs 47%)
- Dramatically lower bronchopulmonary dysplasia rates (3% vs 32%, RR 0.10)
- These benefits were independent of gestational age, birth weight, sex, or race 4
Chorioamnionitis neuroprotection: A 2016 double-blind trial demonstrated that antenatal and postnatal NAC (100 mg/kg IV every 6 hours until delivery) was safe, preserved cerebrovascular regulation, and increased anti-inflammatory markers without adverse cardiovascular effects 5.
Preterm birth prevention: A 2009 trial in women with previous preterm birth and treated bacterial vaginosis showed that oral NAC 0.6g daily plus progesterone significantly increased gestational age at delivery (37.4 vs 34.1 weeks) and reduced recurrent preterm birth 6.
Dosing Considerations
The evidence supports different dosing regimens depending on indication:
- Acetaminophen toxicity: Standard FDA-approved IV protocol
- Impending preterm birth (moderate risk): Oral 80 mg/kg/day for 7 days, then 40 mg/kg/day until 37 weeks or delivery 7
- Impending preterm birth (severe risk): IV bolus 20 mg/kg over 1 hour, then infusion 105 mg/kg over 4 hours, followed by oral maintenance 7
- Triple I/chorioamnionitis: IV 100 mg/kg every 6 hours until delivery 4, 5
Important Caveats
While NAC appears safe, a 2026 pilot trial found that high-dose antenatal NAC failed to restore umbilical cord glutathione levels despite trends toward prolonged pregnancy and reduced neonatal morbidity 7. This suggests the mechanism of benefit may not be solely through glutathione restoration.
The drug label notes that NAC should be used with caution during breastfeeding as it is unknown whether NAC is excreted in human milk 1.
Bottom line: NAC should be used during pregnancy when there is a clear maternal indication (acetaminophen toxicity, severe AFLP requiring ICU care) or when participating in clinical trials for emerging indications like Triple I or preterm birth prevention, where early evidence suggests meaningful neonatal benefits without maternal or fetal harm.